Effect of dipeptidyl peptidase-4 inhibitors on plasma adiponectin: A systematic review and meta-analysis of randomized controlled trials

Current Medicinal Chemistry

Volumn 23, Issue 13, 2016, Pages 1356-1369

  Sahebkar, Amirhossein ^a,b   Ponzo, Valentina ^c   Bo, Simona ^a,c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Adiponectin; Cardiovascular diseases; Dipeptidyl peptidase 4 inhibitors; Meta analysis; Systematic review; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ALOGLIPTIN; ANAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; LINAGLIPTIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; TENELIGLIPTIN; VILDAGLIPTIN; DIPEPTIDYL PEPTIDASE IV;

BIBLIOGRAPHIC DATABASE; DRUG EFFICACY; GOOGLE SCHOLAR; HUMAN; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PUBLISHING; QUANTITATIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; BLOOD; CHEMISTRY; METABOLISM;

ADIPONECTIN; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84974727366     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160405111354     Document Type: Review

References (72)

1. Tasyurek, H.M.; Altunbas, H.A.; Balci, M.K.; Sanlioglu, S. Incretins: their physiology and application in the treatment of diabetes mellitus. Diabetes Metab. Res. Rev., 2014, 30, 354-371.
2. Tan, T.M.; Field, B.C.; McCullough, K.A.; Troke, R.C.; Chambers, E.S.; Salem, V.; Gonzalez Maffe, J.; Baynes, K.C.; De Silva, A.; Viardot, A.; Alsafi, A.; Frost, G.S.; Ghatei, M.A.; Bloom, S.R. Co-administration of glucagonlike peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes, 2013, 62, 1131-1138.
3. Kim, S.J.; Nian, C.; McIntosh, C.H. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J. Biol. Chem., 2007, 282, 34139-34147.
4. Pala, L.; Pezzatini, A.; Dicembrini, I.; Ciani, S.; Gelmini, S.; Vannelli, B.G.; Cresci, B.; Mannucci, E.; Rotella, C.M.. Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetol., 2012, 49, S59-S63.
5. Ussher, J.R.; Drucker, D.J. Cardiovascular action of incretin-based therapies. Circ. Res., 2014, 114, 1788-1803.
6. Stonehouse; A.H.; Darsow, T.; Maggs, D.G. Incretin-based therapies. J. Diabetes, 2012, 4, 55-67.
7. Herman, G.A.; Bergman, A.; Stevens, C.; Kotey, P.; Yi, B.; Zhao, P.; Dietrich, B.; Golor, G.; Schrodter, A.; Keymeulen, B.; Lasseter, K.C.; Kipnes, M.S.; Snyder, K.; Hilliard, D.; Tanen, M.; Cilissen, C.; De Smet, M.; de Lepeleire, I.; Van Dyck, K.; Wang. A.Q.; Zeng, W.; Davies, M.J.; Tanaka, W.; Holst, J.J.; Deacon, C.F.; Gottesdiener, K.M.; Wagner, J.A. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2006, 91, 4612-4619.
8. Derosa, G.; Maffioli, P.; Salvadeo, S.A.; Ferrari, I.; Ragonesi, P.D.; Querci, F.; Franzetti, I.G.; Gadaleta, G.; Ciccarelli, L.; Piccinni, M.N.; D'Angelo, A.; Cicero, A.F. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism , 2010, 59, 887-895.
9. Derosa, G.; Ragonesi, P.D.; Carbone, A.; Fogari, E.; Bianchi, L.; Bonaventura, A.; Romano, D.; Cicero, A.F.; Maffioli, P. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol. Ther., 2012, 14, 475-484.
10. Derosa, G.; Carbone, A.; Franzetti, I.; Querci, F.; Fogari, E.; Bianchi, L.; Bonaventura, A.; Romano, D.; Cicero, A.F.; Maffioli, P. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β -cell function and insulin resistance in type 2 diabetic patients. Diabetes Res. Clin. Pract., 2012, 98, 51-60.
11. Rizzo, M.R.; Barbieri, M.; Marfella, R.; Paolisso, G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes. Diabetes Care, 2012, 35, 2076-2082.
12. Kubota, Y.; Miyamoto, M.; Takagi, G.; Ikeda, T.; Kirinoki-Ichikawa, S.; Tanaka, K.; Mizuno, K. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J. Korean Med., 2012, 27, 1364-1370.
13. Forst, T.; Dworak, M.; Berndt-Zipfel, C.; Löffler, A.; Klamp, I.; Mitry, M.; Pfützner, A. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients withtype 2 diabetes mellitus. Diabetes Obes. Metab., 2013, 15, 576-579.
14. Derosa, G.; Bonaventura, A.; Bianchi, L.; Romano, D.; Fogari, E.; D'Angelo, A.; Maffioli P. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes. Diabet. Med., 2014, 31, 1515-1523.
15. Shimoda, S.; Iwashita, S.; Sekigami, T.; Furukawa, N.; Matsuo, Y.; Ichimori, S.; Goto, R.; Maeda, T.; Watanabe, E.; Kondo, T.; Matsumura, T.; Motoshima, H.; Nishida, K.; Araki, E. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. J. Diabetes Invest., 2014, 5, 320-326.
16. Koska, J.; Sands, M.; Burciu, C.; Reaven, P. Cardiovascular effects of dipetidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diab. Vasc. Dis. Res., 2015, 12, 154-163.
17. Advani, A.; Bugyei-Twum, A.; Connelly, K.M. Cardiovascular effect of incretines in diabetes. Can. J. Diabetes, 2013, 37, 309-314.
18. Monami, M.; Ahrén, B.; Dicembrini, I.; Mannucci, E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab., 2013; 15:112-120.
19. Oyama, J.; Higashi, Y.; Node, K. Do incretins improve endothelial function? Cardiovasc. Diabetol., 2014, 13, 21.
20. Scirica, B.M.; Bhatt, D.L.; Braunwald, E.; Steg, P.G.; Davidson, J.; Hirshberg, B.; Ohman, P.; Frederich, R.; Wiviott, S.D.; Hoffman, E.B.; Cavender, M.A.; Udell, J.A.; Desai, N.R.; Mosenzon, O.; McGuire, D.K.; Ray, K.K.; Leiter, L.A.; Raz, I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med., 2013, 369, 1317-1326.
21. White, W.B.; Cannon, C.P.; Heller, S.R.; Nissen, S.E.; Bergenstal, R.M.; Bakris, G.L.; Perez, A.T.; Fleck, P.R.; Mehta, C.R.; Kupfer, S.; Wilson, C.; Cushman, W.C.; Zannad, F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med., 2013, 369, 1327-1335.
22. Agarwal, S.; Parashar, A.; Menon, V. Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate. Am. J. Cardiovasc. Drugs, 2014, 14, 191-207.
23. Dai, Y.; Dai, D.; Mercanti, F.;, Ding, Z.; Wang, X.; Mehta, J.L. Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach. Acta Diabetol., 2013, 50, 827-835.
24. Ishii, M.; Shibata, R.; Kondo, K.; Kambara, T.; Shimizu, Y.; Tanigawa, T.; Bando, Y.K.; Nishimura, M.; Ouchi, N.; Murohara, T. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism. J. Biol. Chem., 2014, 289, 27235-27245.
25. Hibuse, T.; Maeda, N.; Kishida, K.; Kimura, T.; Minami, T.; Takeshita, E.; Hirata, A.; Nakagawa, Y.; Kashine, S.; Oka, A.; Hayashi, M.; Nishizawa, H.; Funahashi, T.; Shimomura, I. A pilot three month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study. Cardiovasc. Diabetol., 2014, 13, 96.
26. Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; Hara, K.; Mori, Y.; Ide, T.; Murakami, K.; Tsuboyama-Kasaoka, N.; Ezaki, O.; Akanuma, Y.; Gavrilova, O.; Vinson, C.; Reitman, M.L.; Kagechika, H.; Shudo, K.; Yoda, M.; Nakano, Y.; Tobe, K.; Nagai, R.; Kimura, S.; Tomita, M.; Froguel, P.; Kadowaki, T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 2001, 7, 941-946.
27. Funahashi, T.; Matsuzawa, Y. Adiponectin and the cardiometabolic syndrome: an epidemiological perspective. Best Pract. Res. Clin. Endocrinol. Metab., 2014, 28, 93-106.
28. Pischon, T.; Girman, C.J.; Hotamisligil, G.S.; Rifai, N.; Hu, F.B.; Rimm, E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 2004, 291, 1730-1737.
29. Yamauchi, T.; Kadowaki, T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int. J. Obesity, 2008, 32, S13-S18.
30. Mikada, A.; Narita, T.; Yokoyama, H.; Yamashita, R.; Horikawa, Y.; Tsukiyama, K.; Yamada, Y.. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. ''The MASTER randomized, controlled trial''. Diabetes Res. Clin. Pract., 2014, 106, 538-547.
31. Sahebkar, A.; Simental-Mendía, L.E.; Pedone, C.; Ferretti, G.; Nachtigal, P.; Bo, S.; Derosa, G.; Maffioli, P.; Watts, G.F. Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. Br. J. Clinical. Pharmacol., 2015, [Epub ahead of print], DOI: 10.1111/bcp.12854
32. Sahebkar, A.; Serban, C.; Mikhailidis, D.P.; Undas, A.; Lip, G.Y.H; Muntner, P.; Bittner, V.; Ray, K.K.; Watts, G.F.; Hovingh, G.K.; Rysz, J.; Kastelein, J.J.P.; Banach, M. Association between statin use and plasma D-dimer levels, A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost., 2015, 114(3), 546-557.
33. Sahebkar, A. A systematic review and meta-analysis of the effects of pycnogenol on plasma lipids. J. Cardiovasc. Pharmacol. Ther., 2014, 19, 244-255.
34. Sahebkar, A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr. Rev., 2013, 71, 822-835.
35. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 2009, 339, b2535
36. Higgins, J.P.T.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. London: The Cochrane Collaboration, 2009.
37. Borenstein, M.; Hedges, L.; Higgins, J.; Rothstein, H. Comprehensive Meta-Analysis Version 2. Biostat: Englewood NJ, 2005
38. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol., 2005, 5, 13.
39. Sahebkar, A. Does PPARã(2) Gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol, 2013, 32,188-198.
40. Sahebkar, A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res., 2014, 28, 633-642.
41. Duval, S.; Tweedie, R. Trim and fill: a simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis. Biometrics, 2000, 56, 455-463.
42. Miyagawa, K.; Kondo, T.; Goto, R.; Matsuyama, R.; Ono, K.; Kitano, S.; Kawasaki, S.; Igata, M.; Kawashima, J.; Matsumura, T.; Motoshima, H.; Araki, E. Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Cardiovasc. Diabetol., 2013, 12, 160.
43. Hemmeryckx, B.; Swinnen, M.; Gallacher, D.J.; Rong Lu, H.; Roger Lijnen, H. Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice. Eur. J. Pharmacol., 2014, 723, 175-180.
44. Lim, S.; Choi, S.; Shin, H.; Cho, B.; Park, H. Effect of a dipeptidyl peptidaseôIV inhibitor, desôfluoroôsitagliptin, on neointimal formation after balloon injury in rats. PLoS One, 2012, 7, e35007.
45. Sakr, H.F. Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats:possible role of adiponectin receptors 1. J. Physiol. Pharmacol., 2013, 64, 613-623.
46. Moritoh, Y.; Takeuchi, K.; Asakawa, T.; Kataoka, O.; Odaka, H. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β-cell function in db/db mice. Br. J. Pharmacol,. 2009, 157, 415-426.
47. Suzuki, K.; Watanabe, K.; Suzuki, T.; Ouchi, M.; Futami-Suda, S.; Igari, Y.; Nakano, H.; Oba, K. Sitagliptin improves vascular endothelial function in Japanese type 2 diabetes patients without cardiovascular disease. J. Diab. Mellitus, 2012, 2, 338-345.
48. Hashikata, T.; Yamaoka-Tojo, M.; Kakizaki, R.; Nemoto, T.; Fujiyoshi, K.; Namba, S.; Kitasato, L.; Hashimoto, T.; Kameda, R.; Maekawa, E.; Shimohama, T.; Tojo, T.; Ako, J. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes. Heart Vessels., 2015, [Epub ahead of print].
49. Noda, Y.; Miyoshi, T.; Oe, H.; Ohno, Y.; Nakamura, K.; Toh, N.; Kohno, K.; Morita, H.; Kusano, K.; Ito, H. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report. Cardiovasc Diabetol., 2013, 12, 8.
50. Lamers, D.; Famulla, S.; Wronkowitz, N.; Hartwig, S.; Lehr, S.; Ouwens, D.M.; Eckardt, K.; Kaufman, J.M.; Ryden, M.; Müller, S.; Hanisch, F.G.; Ruige, J.; Arner, P.; Sell, H.; Eckel, J. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes, 2011, 60, 1917-1925.
51. Yang, W.S.; Lee, W.J.; Funahashi, T.; Tanaka, S.; Matsuzawa, Y.; Chao, C.L.; Chen, C.L.; Tai, T.Y.; Chuang, L.M. Weight reduction increases plasma levels of an adiposederived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab., 2001, 86, 3815-3819.
52. Hossain, M.; Mukheem, A.; Kamarul, T. The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin. Life Sci., 2015, 135, 55-67.
53. Kim Chung, L.T.; Hosaka, T.; Yoshida, M.; Harada, N.; Sakaue, H.; Sakai, T.; Nakaya, Y. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem. Biophys. Res. Commun., 2009, 390, 613-618.
54. Li, L.; Yang, G.; Li, Q.; Tan, X.; Liu, H.; Tang, Y.; Boden, G. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes. Metab., 2008, 10, 921-930.
55. Mason R.P.; Jacob, R.F.; Kubant, R.; Ciszewski, A.; Corbalan, J.J.; Malinski, T. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J. Cardiovasc. Pharmacol., 2012, 60, 467-473.
56. Liu, L.; Liu, J.; Wong, W.T.; Tian, X.Y.; Lau, C.W.; Wang, Y.X.; Xu, G.; Pu, Y.; Zhu, Z.; Xu, A.; Lam, K.S.; Chen, Z.Y.; Ng, C.F.; Yao, X.; Huang, Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension, 2012, 60, 833-841.
57. Shah, Z.; Kampfrath, T.; Deiuliis, J.A.; Zhong, J.; Pineda, C.; Ying, Z.; Xu, X.; Lu, B.; Moffatt-Bruce, S.; Durairaj,R.; Sun, Q.; Mihai, G.; Maiseyeu, A.; Rajagopalan, S. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation, 2011, 124, 2338-2349.
58. Matsubara, J.; Sugiyama, S.; Sugamura, K.; Nakamura, T.; Fujiwara, Y.; Akiyama, E.; Kurokawa, H.; Nozaki, T.; Ohba, K.; Konishi, M.; Maeda, H.; Izumiya, Y.; Kaikita, K.; Sumida, H.; Jinnouchi, H.; Matsui, K.; Kim-Mitsuyama, S.; Takeya, M.; Ogawa, H. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J. Am. Coll. Cardiol., 2012, 59, 265-276.
59. Huang, C.Y.; Shih, C.M.; Tsao, N.W.; Lin, Y.W.; Huang, P.H.; Wu, S.C.; Lee, A.W.; Kao, Y.T.; Chang, N.C., Nakagami, H.; Morishita, R.; Ou, K.L.; Hou, W.C.; Lin, C.Y.; Shyu, K.G.; Lin, F.Y. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br. J. Pharmacol., 2012, 167, 1506-1519.
60. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care, 2011, 34, 2072-2077.
61. Ouchi, N.; Kobayashi, H.; Kihara, S.; Kumada, M.; Sato, K.; Inoue, T.; Funahashi, T.; Walsh, K. Adiponectin stimulates angiogenesis by promoting cross-talk between AMPactivated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem., 2004, 279, 1304-1309.
62. Gonçalves, A.; Marques, C.; Leal, E.; Ribeiro, C.F.; Reis, F.; Ambrósio, A.F.; Fernandes, R. Dypeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochim. Biophys. Acta, 2014, 1842, 1454-1463.
63. Mega, C.; Vala, H.; Rodrigues-Santos, P.; Oliveira, J.; Teixeira, F.; Fernandes, R.; Reis, F.; Teixeira Lemos, E. Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties. Diabetol. Metab. Syndr., 2014, 6, 42.
64. Omar, B.A.; Vikman, J.; Winzell, M.S.; Voss, U.; Ekblad, E.; Foley, J.E.; Ahrén, B. Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advancedaged diet-induced obesity mouse model. Diabetologia, 2013, 56, 1752-1760.
65. Gonçalves, A.; Leal, E.; Paiva, A.; Teixeira Lemos, E.; Teixeira, F.; Riberiro, C.F.; Reis, F.; Ambrósio, A.F.; Fernandes, R. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diab. Obes. Metab., 2012, 14, 454-463.
66. Marques, C.; Mega, C.; Gonçalves, A.; Rodrigues-Santos, P.; Teixeira-Lemos, E.; Teixeira, F.; Fontes-Ribeiro, C.; Reis, F.; Fernandes, R. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflam., 2014, ID 538737.
67. Pharm, S.K.B.; Khan, S.; Panda, B.P.; Akhtar, M.; Najimi, A.K. Potential effects of vildagliptin on biomarkers associated with prothrombosis in diabetes mellitus. Exp. Opin. Therap. Targ., 2015, 19, 1607-1616.
68. Barbieri, M.; Rizzo, M.R.; Marfella, R.; Boccardi, V.; Esposito, A.; Pansini, A.; Paolisso, G. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis, 2013, 227, 349-354.
69. Read, P.A.; Khan, F.Z.; Heck, P.M.; Hoole, S.P.; Dutka, D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ. Cardiovasc. Imaging, 2010, 3, 195-201.
70. McCormick, L.M.; Kydd, A.C.; Read, P.A.; Ring, L.S.; Bond, S.J.; Hoole, S.P.; Dutka, D.P. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circ. Cardiovasc. Imaging, 2014, 7, 274-281.
71. Penn, M.S.; Mendelsohn, F.O.; Schaer, G.L.; Sherman, W.; Farr, M.; Pastore, J.; Rouy, D.; Clemens, R.; Aras, R.; Losordo, D.W. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ. Res., 2013, 112, 816-825.
72. Marfella, R.; Barbieri, M.; Grella, R.; Rizzo, M.R.; Nicoletti, G.F.; Paolisso, G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J. Diab. Compl., 2010, 24, 79-83.